This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SUNDAY, Oct. 6, 2024 — Pain, tingling and cramps in your legs and feet may be giving you a warning.They could be signs of poor blood circulation, which can lead to serious heart and health problems if left untreated, according to a doctor at Baylor.
Alzheimer's disease (AD) is a progressive age-related neurodegenerative disorder characterized by loss of memory and other cognitive functions. The problem of this disease is even more fundamental because the available therapies only provide symptomatic relief without addressing the basic factor of the disease. This review article comprehensively summarized the recent advancement in memantine and its hybrid analogs as potential disease-modifying agents for the management of AD.
By Paul D. Rennert, SugarCone Biotech LLC. Cell surface degraders are weird but cool. There is an emerging class of therapeutics, brilliant really, that make use of cell surface proteins that will respond to antibody binding by moving quickly inside the cell and then shuttling over to lysosomes for degradation. The trick is bind to these “internalizer proteins” with a bispecific antibody or fusion protein so they drag a second bound targeted protein with them.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Tom Ireland writes about technological advances — and roadblocks — in artificial wombs for Issue 04 of Asimov Press. The womb is a remarkable organ — a muscular, pear-shaped chamber that supports the transformation of a tiny cluster of dividing cells into an entirely new person. All humans begin their lives in this sturdy chamber. At least for now.
Marijuana, Psychosis, and Policy Development "Two things are needed to move beyond policy-biased appraisals of the evidence on cannabis and psychosis. "First, we need to use explicit criteria to assess the evidence for contributory causal relationships and apply them in an even-handed and consistent way. We should avoid the example of the tobacco industry in setting such a high standard of evidence for a causal inference that no evidence can satisfy it ( 30 ).
Marijuana, Psychosis, and Policy Development "Two things are needed to move beyond policy-biased appraisals of the evidence on cannabis and psychosis. "First, we need to use explicit criteria to assess the evidence for contributory causal relationships and apply them in an even-handed and consistent way. We should avoid the example of the tobacco industry in setting such a high standard of evidence for a causal inference that no evidence can satisfy it ( 30 ).
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content